Resources available for HIV in low and middle income countries have increased dramatically since 2002, with over $46.5 billion invested globally between 2011-2020. This new investment framework prioritizes basic prevention and treatment programs, key populations, and social enablers in order to work towards objectives of stopping new HIV infections and keeping people alive. Modeling shows this approach could avert over 12 million new infections and 7.4 million deaths by optimizing synergies across interventions.

1. !"#$%"&#'$()*$#)"+,-*$%.,/"0.,")1$"2$(3.#($")."!&45"
"
6.,$"7-89$"0.,")1$"6.#$:"%;)1;#"-"+,-*$%.,/".0"
51-,$<"2$(3.#(;=;8;):"

2. Resources available for HIV
in low and middle income countries, 1986-2010

3. We have done a
lot…
! >#3,$?$<$#)$<"(?-8$"93".0"@&7"
3,$'$#A.#B"),$-)*$#)B"?-,$"-#<"
(933.,)"
! 4$?8;#$";#",-)$".0"#$%"@&7"
;#0$?A.#(";#"*-#:"?.9#),;$("
! 6.,$")1-#"CDC"*;88;.#"3$.38$".#"
!2E"
! 6;88;.#(".0".,31-#(",$?$;';#F"=-(;?"
$<9?-A.#B"1$-8)1B"(.?;-8"3,.)$?A.#"

4. But we can do
better
5?-8$"93")."<-)$"F9;<$<"=:"-"
G?.**.<;):"-33,.-?1H"
"
! >#(:()$*-A?"3,;.,;A(-A.#"-#<"
;#'$()*$#)"%;)1"8;*;)$<"=-(;(";#"
?.9#),:"$3;<$*;.8.F:"-#<"?.#)$I)"
! 2$(.9,?$("(3,$-<")1;#8:"-?,.(("
*-#:"3-,-88$8";#)$,'$#A.#("
! +.?9(".#"<;(?,$)$";#)$,'$#A.#("
,-)1$,")1-#".'$,-88",$(98)("8$-<;#F"
)."-"0,-F*$#)$<",$(3.#($"

5. New Investment Framework
CRITICAL BASIC PROGRAMME ACTIVITIES OBJECTIVES
ENABLERS
Social enablers Key Children &
populations mothers
• Political commitment &
Stopping new
advocacy
• Laws, policies & infections
practices
• Community mobilization Behaviour
• Stigma reduction change Condoms
• Mass media
• Local responses, to
change risk
environment
Programme enablers Keeping
• Community-centered people alive
design & delivery
• Programme
communication Care & Male
• Management & incentives treatment circumcision
• Production & distribution
• Research & innovation
SYNERGIES WITH DEVELOPMENT SECTORS
Social protection; Education; Legal Reform; Gender equality; Poverty reduction; Gender-based violence;
Health systems (incl. treatment of STIs, blood safety); Community systems; Employer practices.

6. Three investment scenarios
Impact on the epidemic
%"
%!
$"
>54"JK;88;.#(L"
$!
K9(;#$(("-("9(9-8"
#" M"NDO"
R$%"@&7"&#0$?A.#("
M"NDP"
J*;88;.#(L"
#!
M"QDO"
" M"QDP"
M"PDO"
! M"P"
$!## $!#$ $!#% $!#& $!#" $!#' $!#( $!#) $!#* $!$!

7. Three investment scenarios
Impact on the epidemic
%"
%!
$"
>54"JK;88;.#(L"
$! &#'$()*$#)"0,-*$%.,/"
K9(;#$(("-("9(9-8"
#" M"NDO"
R$%"@&7"&#0$?A.#("
M"NDP"
J*;88;.#(L"
#!
M"QDO"
" M"QDP"
M"PDO"
! M"P"
$!## $!#$ $!#% $!#& $!#" $!#' $!#( $!#) $!#* $!$!

8. Three investment scenarios
Impact on the epidemic
%"
2-3;<"(?-8$"93"
3,$';.9("3,.S$?A.#("
%!
$"
>54"JK;88;.#(L"
$! &#'$()*$#)"0,-*$%.,/"
K9(;#$(("-("9(9-8"
#" M"NDO"
R$%"@&7"&#0$?A.#("
M"NDP"
J*;88;.#(L"
#!
M"QDO"
" M"QDP"
M"PDO"
! M"P"
$!## $!#$ $!#% $!#& $!#" $!#' $!#( $!#) $!#* $!$!

9. E1$"#$%";#'$()*$#)"0,-*$%.,/"
+.?9(".#"%1-)"*-/$("-"<;T$,$#?$"
>54"JK;88;.#(L"
$"
$!
5:#$,F;$("
#"
V,;A?-8"W#-=8$,("
#!
" K-(;?"U,.F,-**$"
!?A';A$("
!
$!## $!#$ $!#% $!#& $!#" $!#' $!#( $!#) $!#* $!$!

10. ART coverage in 2015 by CD4 count
#!!"
CD4 350
+!"
*!"
15 million
)!"
(!"
V.'$,-F$
'!"
&!"
%!"
T4P 13.1 million (health)
$!"
#!"
!"
,'!! %'!-&++ $'!-%&+ $!!-$&+ #!!-#++ '!-++ .'!
V4X"V.9#)"J?$88(Y*8L

11. Returns on investment of new
investment framework (2011-2020)
Outcomes
Total infections averted More than 12 million
Infant infections averted 1.9 million
Deaths averted 7.4 million
Life years gained 29.4 million

12. New investment framework: the tipping point
R$%8:"$8;F;=8$"0.,"),$-)*$#)"
R$%8:";#0$?)$<"

13. New infections, behaviour change and treatment
coverage in Botswana
Behaviour change
New infections and
treatment coverage

14. Cost and economic returns
2011 to 2020
Cost/Returns
Total additional investment
US$46.5 Billion
(over 10 years)
Future treatment need
US$40 Billion
averted
US$1,060
Life years gained
per life year gained

15. Investment framework projections for new HIV
infections
Optimized investment will lead to rapid declines in new HIV infections in many countries

16. V.**9#;):"*.=;8;Z-A.#"-((9*3A.#(";#")1$"
;#'$()*$#)"0,-*$%.,/""
V.()"$#'$8.3$["?.**9#;):"*.=;8;(-A.#"?.*3.#$#)".0")1$"
?,;A?-8"$#-=8$,("""
"
////$!##//0!1%23/ //$!#'/0!1(/23/
/ /$!$!/0#1!/23//
/
!((9*3A.#(["
• 43567897:/5;<<=3>?@/58A85>?@//
• >3567897:/5;<<=3>?@/976B>57/:7C>B76@///
• 377:/D;6/67<=3768E;3/;D/5;<<=3>?@/83:/C8@/F;6G769//
• 377:/D;6/?68>3>3HI/H=>:8357I/9=A76B>9>;3/
• A86E5>A8E;3/;D/A7;AC7/C>B>3H/F>?J/K4L/

17. V.**9#;):"*.=;8;Z-A.#["*-/$("(?-8$"93"3.((;=8$""
• R9*=$,".0"3$.38$")$()$<")1,.9F1"?.**9#;):"
*.=;8;Z-A.#""
/$!#!M/&(/<>CC>;3/NLOPQ/// /$!#'M/#!+/<>CC>;3//
/
• 5$,';?$"<$8;'$,:"?.()("J),$-)*$#)L""
/$!#!M/0#)+/A76/@786///
/$!$!M/0#$'/A76/@786/N0#)/>3/C;F/>35;<7/5;=3?6>79Q//
/
• 4,;';#F"?.()("<.%#["0$%$,".9)3-A$#)"';(;)(B"
?.**9#;):"(933.,)"($,';?$"*.<-8;A$("
• K$$,"@$-8)1"]9)?.*$("

18. V.**9#;):"*.=;8;Z-A.#[""
;#?,$-($("$T$?A'$#$(("
• O;<<=3>?@/<;2>C>98E;3/>3567897:/K4L/?79E3H/68?79/D;=6-
D;C:/>3/P83R83>8I/S><282F7I/T;=?J/UD6>58/83:/PJ8>C83:1/
//
• O;39>9?73?/5;3:;</=97/>3/A89?/#$/<;3?J9/&/E<79/J>HJ76/>3/
5;<<=3>E79/F>?J/H;;:/5;<<=3>?@/73H8H7<73?/NV73@8Q//
//
• K@A;?J7E58C/5>65=<5>9>;3/<;:7C/VF8S=C=-W8?8C/M//
– 5;67/>3?76B73E;3M//$&!I!!!/>3D75E;39/8B76?7:/;B76/?73/@7869/
– F>?J/7382C769M/&$!I!!!/>3D75E;39/8B76?7:I/F>?J/<;:79?/
<86H>38C/>3567897/>3/5;9?9/
/

19. Investement framework allocation in 2015

20. E-#Z-#;-["-##9-8"#$%"@&7";#0$?A.#(B"NPQQMNPNP"
#(!!!!/
#&!!!!/ K-($8;#$"J=9(;#$(("-("9(9-8L"
#$!!!!/
#!!!!!/
*!!!!/
(!!!!/
&#'$()*$#)"+,-*$%.,/"
&!!!!/
$!!!!/
!/
$!##/ $!#$/ $!#%/ $!#&/ $!#'/ $!#(/ $!#)/ $!#*/ $!#+/ $!$!/

21. E-#Z-#;-["-##9-8"!&45"<$-)1(B"NPQQMNPNP"
#&!!!!/
K-($8;#$"J=9(;#$(("-("9(9-8L"
#$!!!!/
#!!!!!/
*!!!!/
(!!!!/
&!!!!/ &#'$()*$#)"+,-*$%.,/"
$!!!!/
!/
$!##/$!#$/$!#%/$!#&/$!#'/$!#(/$!#)/$!#*/$!#+/$!$!/

24. Resources available for HIV
in low and middle income countries, globally, 2002-2010

25. Percentage of care and treatment
expenditure from international sources

26. Few donors meet the development assistance targets
Norway 1.10%
Luxembourg 1.09%
Sweden 0.97%
Denmark 0.90%
Netherlands 0.81%
Belgium 0.64%
United Kingdom 0.56%
Finland 0.55%
Ireland 0.53%
France 0.50%
Spain 0.43%
Switzerland 0.41% Net development assistance
Germany 0.38%
Canada 0.33% in 2001 as % of gross
Austria
Australia
0.32%
0.32%
national income
Portugal 0.29%
New Zealand 0.26%
United States 0.21%
Japan 0.20%
Greece 0.17%
Italy 0.15%
Korea 0.12%
0% 0.3% 0.5% 0.7% 1% 1.2%

27. Measuring national commitment to AIDS:
the Domestic Investment Priority Index
SOURCE: UNAIDS expenditure data; WHO data on the burden disease; and economic data from the International Monetary Fund World Economic Outlook database

28. Economic growth in Africa, 1970–2010
Third-fastest growing region in the World

29. Three options for increasing domestic public HIV
investment in Africa

30. Projected resource needs (in USD billion)
Assumed increases of domestic contributions by BRICS and others
within ability to pay (economic growth and towards Abudja targets)
Development Assistance
8.0
10.7 9.4
12.7 11.8
13.6 13.5
13.0
11.9
11.3
Domestic financing
9.7
LI
LMI
UMI
XY4OT/

31. T;<7/Z=79E;39
/
• [J8?/867/?J7/9?68?7H>5/;A73>3H9/D;6/8/37F/
:>8C;H=7/86;=3:/75>735@]/
• U67/?J767/;2B>;=9/<>9-<8?5J79/27?F773/?J7/
7A>:7<>5/83:/?J7/679A;397]/
• [J>5J/867/?J7/D85?;69/?J8?/<8G7/>?/:>5=C?/?;/
958C7/=A/289>5/A6;H68<<7/5;<A;373?9]//
• K;F/5;=C:/A86?3769/J7CA/>3/8AAC>58E;3/;D/?J7/
4^/8AA6;85J/

32. The beginning of the end of
AIDS is in our hands

34. Y785J>3H/A7;AC7/F>?J/976B>579M
/
_`8<AC79/D;6/$!#'/
V.'$,-F$"
J3.398-A.#",$-?1$<L
"
O;3:;<9/N:>95;6:83?/5;=AC79Q/ (!" /
O;3:;<9/NJ>HJ/6>9G/A;AQ/ '!" /
T7`/F;6G/ (!" /
aTa/A6;H68<<79/ (!" /
4bc/A6;H68<<79/ (!" /
6;88;.#"
K4L/?79E3H/ %$! /
UYP/NOb&/%'!I/P&dQ/ ?;F86:9/#' /

35. O;9?/A76/A8E73?/A76/@786/
/
NF7>HJ?7:/8B768H7/>3/cT0Q
/
" " " " "NPQP " "NPQO " "NPNP"
/
e82/N37F/A8E73?9Q/////// /#*!//// / /#$+/ / /)+//
/
e82/N5;3?/A8E73?9Q//////// /#*!/ / /#$*/ / /)(//
/
T76B>57/:7C>B76@/ / /#)(/ / /#&&/ / /##$//
/
#9?/e>37/UYL9/ / / /#'' / /#&)/ / /')//
/
$3:/e>37/UYL9/ / / /#()* / /+*& / /$+'//

36. P79E3H/83:/O;=397C>3H /
O;B768H7/83:/5;9?/A76/A769;3/
!"#$%&'(%)*+',$%)"-,#'**'.%/,.%$'#$'.
0:1
091
081
071
061
051
041
031
021
01
1;
6;
;
;
;
;
;
;
;
;
;
;
;
;
;
;
;
26
36
46
56
66
76
86
96
:6
12
14
16
31
51
86
1<
1<
1<
1<
1<
1<
!"='(/>'

37. fTP/O;9?/U99=<AE;39
/
V.()".0"6$)1-<.#$[""
• %%5/D;6/*!<H/>3/4683/?;/0$1!(/D;6/*!<H/>3/
43:;379>8/
• U2;=?/cTb/#!!!/A76/A769;3/@786/
• g;>3H/:;F3/2@/$!"/>3/$!#'/83:/2@/J8CD/>3/
$!$!/

38. X7J8B>;6/OJ83H7/d6;H68<<79
/
• e>hC7/7B>:7357/D;6/7i75EB73799/
• e>hC7/>3D;6<8E;3/;3/5;9?/
• U9/8/A6;`@M/5;9?/F;6GAC857/A6;H68<9/N2@/$!#'I/
'!"/5;B768H7/;D/?J7/#&*/<>CC>;3/7<AC;@779/>3/
?J7/D;6<8C/975?;6/>3/5;=3?6>79/F>?J/
H73768C>R7:/7A>:7<>59I/8B768H7/=3>?/5;9?/;D/cT
0/+/A76/7<AC;@77/A76/@786Q//

39. O;<<=3>?@/a;2>C>R8E;3/
• e>hC7/>3D;6<8E;3/;3/5;9?/
/
• O;=3?6@/67B>7F9/NcTb/#/?;/#&/A76/8:=C?/
A;A=C8E;3Q/
/
• O;<<=3>?@/K78C?J/[;6G769/Nj/cTb/$/A76/
8:=C?/A;A=C8E;3Q//